Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to Sell

StockNews.com downgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research note released on Wednesday morning.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity Group restated a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Finally, Chardan Capital restated a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Seres Therapeutics currently has an average rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Trading Up 7.1 %

Shares of Seres Therapeutics stock opened at $0.98 on Wednesday. The business’s 50-day moving average price is $0.81 and its 200-day moving average price is $0.90. The firm has a market capitalization of $167.33 million, a PE ratio of -3.98 and a beta of 2.06. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $2.05.

Institutional Investors Weigh In On Seres Therapeutics

Large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC raised its stake in shares of Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC lifted its holdings in Seres Therapeutics by 49.5% in the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after buying an additional 25,250 shares during the period. Point72 DIFC Ltd bought a new stake in shares of Seres Therapeutics in the 2nd quarter worth approximately $64,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Seres Therapeutics during the second quarter valued at approximately $92,000. Finally, State Street Corp raised its holdings in shares of Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after acquiring an additional 43,700 shares in the last quarter. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.